A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

Journal of the Neurological Sciences

Volumn 216, Issue 1, 2003, Pages 113-118

  Zivadinov, Robert ^a   Zorzon, Marino ^a   Tommasi, Maria Antonietta ^a   Nasuelli, Davide ^a   Bernardi, Monica ^a   Monti Bragadin, Luisa ^a   Cazzato, Giuseppe ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Interferon beta; Longitudinal study; Multiple sclerosis; Quality of life; Relapsing remitting; Side effects

Indexed keywords

BETA1A INTERFERON;

ADULT; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; CHILL; CLINICAL ARTICLE; COGNITION; CORRELATION ANALYSIS; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; INDEPENDENCE; INJECTION; INJECTION SITE; INSOMNIA; MALE; MOOD DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; REMISSION; SIDE EFFECT; SPASTICITY; STATISTICAL SIGNIFICANCE; SYMPTOM;

EID: 0242523134     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00225-9     Document Type: Article

References (33)

1. Interferon beta-1b is effective in relapsing remitting multiple sclerosis: I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
2. Paty D.W., Li D.K.B. Interferon beta-1b is effective in relapsing remitting multiple sclerosis: II. MRI results analysis results of a multicenter, randomised double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
3. Jacobs L.D., Cookfair D.L., Rudick R.A. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
4. Randomized double-blind placebo controlled study of interferonβ-1a in relapsing/remitting multiple sclerosis. Lancet. 352:1998;1491-1497.
5. Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352:1998;1498-1504.
6. Rothwell P.M. Quality of life in multiple sclerosis. JNNP. 65:1998;433.
7. Schwartz C.E., Coulthard-Morris L., Cole B., Vollmer T. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch. Neurol. 54:1999;1475-1480.
8. Arnoldus J.H.A., Killestein J., Pfennings L.E.M.A., Jelles B., Uitdehaag B.M.J., Polman C.H. Quality of life during the first 6 months of interferon beta treatment in patients with MS. Mult. Scler. 6:2000;338-342.
9. Rice G.P., Oger J., Duquette P., Francis G.S., Belanger M., Laplante S. et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J. Neurol. Sci. 26:1999;276-282.
10. Freeman J.A., Thompson A.J., Fitzpatrick R.et al. Interferon beta-1b in the treatment of secondary progressive MS. Impact on quality of life. Neurology. 57:2001;1870-1875.
11. Vermersch P., de Seze J., Delisse B., Lemaire S., Stojkovic T. Quality of life in multiple sclerosis: influence of interferonβ 1a (Avonex) treatment. Mult. Scler. 8:2002;377-381.
12. Cohen J.A., Cutter G.R., Fischer J.S.et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 59:2002;679-687.
13. Blumhardt L. Interferon beta-1a. Hawkins C.P., Wolinsky J.S. Principles of treatments in multiple sclerosis. 2000;38-70 Butterworth-Heinemann, Oxford, UK.
14. Paty D. Interferon beta-1b. Hawkins C.P., Wolinsky J.S. Principles of treatments in multiple sclerosis. 2000;24-37 Butterworth-Heinemann, Oxford, UK.
15. Mohr D.C., Likosky W., Boudewyn A.C.et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult. Scler. 4:1998;487-489.
16. Gottberg K., Gardful A., Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients perception of the side-effects. Mult. Scler. 6:2000;349-354.
17. Poser C.M., Paty D.W., Scheinberg L.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 12:1983;227-231.
18. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
19. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
20. Cella D.F., Dineen K., Arnason B.et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 47:1996;129-139.
21. FIM VERSION 4.0. Guide for the uniform data set for medical rehabilitation (Adult-FIM), version 4.0. Buffalo (NY) 14214: State University of New York at Buffalo; 1994.
22. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
23. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6:1967;278-296.
24. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32:1959;50.
25. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systematic lupus erythemathosus. Arch. Neurol. 46:1989;1121-1123.
26. Janardhan V., Bakshi R. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch. Neurol. 57:2000;1485-1491.
27. Lublin F.D., Whitaker J.N., Eidelman B.H., Miller A.E., Arnason B.G.W., Burks J.S. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 46:1996;12-18.
28. Ware J.E., Snow K.K., Kosinki M., Gandek B. SF-36 health survey. Manual and interpretation guide. 1993;Nimrod Press, Boston, MA.
29. Vickrey B.G., Hays R.D., Harooni R., Myers L.W., Elfison G.W. A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 4:1995;187-206.
30. Burden of illness of multiple sclerosis: Part II. Quality of life. Can J. Neurol. Sci. 25:1998;31-38.
31. Walther E.U., Hohlfeld R. Side effect of interferon beta therapy and their management. Neurology. 53:1999;1622-1627.
32. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
33. Gauci L. Management of cancer patients receiving interferon alpha-2a. Int. J. Cancer. (Suppl. 1):1987;21-30.